236 related articles for article (PubMed ID: 27766611)
1. JCV serology in time: 3 years of follow-up.
Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
3. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
4. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
5. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
6. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
[TBL] [Abstract][Full Text] [Related]
7. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
8. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
9. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
[TBL] [Abstract][Full Text] [Related]
10. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
[TBL] [Abstract][Full Text] [Related]
11. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
[TBL] [Abstract][Full Text] [Related]
12. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
[TBL] [Abstract][Full Text] [Related]
13. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
[TBL] [Abstract][Full Text] [Related]
14. Improving risk-stratification of natalizumab-associated PML.
Tugemann B; Berger JR
Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
[TBL] [Abstract][Full Text] [Related]
15. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
16. Anti-JC virus antibody titres increase over time with natalizumab treatment.
Raffel J; Gafson AR; Malik O; Nicholas R
Mult Scler; 2015 Dec; 21(14):1833-8. PubMed ID: 26449743
[TBL] [Abstract][Full Text] [Related]
17. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
18. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
O'Connor PW
Can J Neurol Sci; 2012 Sep; 39(5):670-5. PubMed ID: 22931715
[No Abstract] [Full Text] [Related]
20. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]